1. The Janus Henderson Global Life Sciences Diversified ADR Managed Account Portfolio returned 5.74% (gross) and the MSCI World Health Care IndexSM returned 5.79%.; 2. Positioning in pharmaceuticals weighed on relative returns, while stock selection in biotechnology contributed to performance.; 3. Innovation and mergers and acquisitions will likely remain tailwinds for healthcare stocks, while the sector's defensive characteristics could appeal to investors in the case of an economic slowdown.
Related Articles
- Pfizer Is Trading As If It's 2009 Again4 months ago
- Pfizer Stock's Upside Got Bigger5 months ago
- Novo Nordisk: Be Greedy When Others Are Fearful7 months ago
- Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)7 months ago
- Pfizer: A Strong Product Pipeline Could Lead To Significant Upside9 months ago
- Amgen's GLP-1 Upside Is Not Priced In11 months ago
- Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors4 months ago
- The Unraveling Of DNA Company 23andMe4 months ago
- Litigation, Debt, And Decline - Yet Bayer Seems Like A Buy4 months ago
- New Paths for the Future: HHN and OPTIMA pharma Enter into a Partnership4 months ago